Evidence map›Paper›PMID 30775563›Full record

ArticleClinical and translational radiation oncology2019

An

Hesham Elhalawani, Baher Elgohari, Timothy A Lin, Abdallah S R Mohamed, Thomas J Fitzgerald, Fran Laurie, Kenneth Ulin, Jayashree Kalpathy-Cramer, Thomas Guerrero, Emma B Holliday and 19 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 3 countries.

Hesham ElhalawaniDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Baher ElgohariDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Timothy A LinDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Abdallah S R MohamedDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Thomas J FitzgeraldImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Fran LaurieImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Kenneth UlinImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jayashree Kalpathy-CramerAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Massachusetts, USA.
Thomas GuerreroDepartment of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.
Emma B HollidayDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Gregory RussoDepartment of Radiation Oncology, Boston Medical Center, Massachusetts, USA.
Abhilasha PatelDepartment of Radiation Oncology, University of Texas Health Sciences Center at San Antonio, TX, USA.
William JonesDepartment of Radiation Oncology, University of Texas Health Sciences Center at San Antonio, TX, USA.
Gary V WalkerDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Musaddiq AwanDepartment of Radiation Oncology, Case Western Reserve University, OH, USA.
Mehee ChoiDepartment of Radiation Oncology, Northwestern University, IL, USA.
Roi DaganUniversity of Florida Health Proton Therapy Institute, FL, USA.
Omar MahmoudDepartment of Radiation Oncology, University of Miami, FL, USA.
Anna ShapiroDepartment of Radiation Oncology, Upstate Cancer Center, SUNY Upstate Medical University, NY, USA.
Feng-Ming Spring KongDepartment of Radiation Oncology, University Hospitals Cleveland Medical Center, OH, USA.
Daniel GomezDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
Jing ZengDepartment of Radiation Oncology, University of Washington Medical Center, WA, USA.
Roy DeckerDepartment of Therapeutic Radiology, Yale University School of Medicine, Connecticut, USA.
Femke O B SpoelstraDepartment of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Laurie E GasparDepartment of Radiation Oncology, Vanderbilt University, TN, USA.
Lisa A KachnicDepartment of Radiation Oncology, Vanderbilt University Medical Center, Tennessee, USA.
Charles R ThomasDepartment of Radiation Medicine, Oregon Health & Science University, Oregon, USA.
Paul OkunieffSWOG, Department of Radiation Oncology, University of Florida College of Medicine, Florida, USA.
Clifton D FullerDepartment of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Massachusetts Chan Medical School · USThe University of Texas Health Science Center at San Antonio · USAmsterdam University Medical Centers · NLBaylor College of Medicine · USBeaumont Health · USBoston Medical Center · USCase Western Reserve University · USFlorida College · USHarvard University · USNorthwestern University · USOregon Health & Science University · USSUNY Upstate Medical University · USUniversity Hospitals of Cleveland · USUniversity of Florida Health · USUniversity of Miami · USUniversity of Washington Medical Center · USVanderbilt University · USVanderbilt University Medical Center · USYale University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2002 to 2012
$26.1M
QUALITY ASSURANCE REVIEW CENTER (QARC)U10CA029511 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, THOMAS J. · 1985 to 2013
$23.4M
NCI National Clinical Trials Network - Lead Academic Participating SiteUG1CA233324 · NCI · UNIVERSITY OF COLORADO DENVER · PI ANTHONY D ELIAS · 2019 to 2026
$5.2M
Informatics Tools for Optimized Imaging Biomarkers for Cancer Research&DiscoveryU24CA180927 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KALPATHY-CRAMER, JAYASHREE, ROSEN, BRUCE R · 2014 to 2018
$3.4M
Quantitative MRI of Glioblastoma ResponseU01CA154601 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KALPATHY-CRAMER, JAYASHREE · 2011 to 2016
$3.4M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
QuBBD: Precision E –Radiomics for Dynamic Big Head & Neck Cancer Data R01CA225190 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$776k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA218148NCI NIH HHS R01 CA225190NCI NIH HHS U01 CA154601NCI NIH HHS U10 CA029511NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA180803NCI NIH HHS U24 CA180927NCI NIH HHS UG1 CA233324NIBIB NIH HHS R25 EB025787NIDCR NIH HHS R56 DE025248
6 · The paper itself

Abstract

introductionTarget delineation variability is a significant technical impediment in multi-institutional trials which employ intensity modulated radiotherapy (IMRT), as there is a real potential for clinically meaningful variances that can impact the outcomes in clinical trials. The goal of this study is to determine the variability of target delineation among participants from different institutions as part of Southwest Oncology Group (SWOG) Radiotherapy Committee's multi-institutional

methodsCT simulation scans were acquired from four patients with Pancoast tumor. Two patients had simulation 4D-CT and FDG-FDG PET-CT while two patients had 3D-CT and FDG-FDG PET-CT. Seventeen SWOG-affiliated physicians independently delineated target volumes defined as gross primary and nodal tumor volumes (GTV_P & GTV_N), clinical target volume (CTV), and planning target volume (PTV).Six board-certified thoracic radiation oncologists were designated as the 'Experts' for this study. Their delineations were used to create a simultaneous truth and performance level estimation (STAPLE) contours using ADMIRE software (Elekta AB, Sweden 2017). Individual participants' contours were then compared with Experts' STAPLE contours.

resultsWhen compared to the Experts' STAPLE, GTV_P had the best agreement among all participants, while GTV_N showed the lowest agreement among all participants. There were no statistically significant differences in all studied parameters for all TVs for cases with 4D-CT versus cases with 3D-CT simulation scans.

conclusionsHigh degree of inter-observer variation was noted for all target volume except for GTV_P, unveiling potentials for protocol modification for subsequent clinically meaningful improvement in target definition. Various similarity indices exist that can be used to guide multi-institutional radiotherapy delineation QA credentialing.

Indexed as

ContouringPancoast tumorQAQuality assuranceTarget volumesThoracic

Identifiers

PMID30775563
PMCPMC6365802
OpenAlexW2906844468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.